封面
市場調查報告書
商品編碼
1616799

個人化醫療的全球市場規模:各產品,各終端用戶,各地區,範圍及預測

Global Personalized Medicine Market Size By Product, By End-User, By Geographic Scope And Forecast

出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

個人化醫療市場規模及預測

2024年個人化醫療市場規模為1,302.3億美元,預估2024年至2031年複合年增長率為10.67%,預估至2031年將達2725.9億美元。個人化醫療(也稱為精準醫療)是一種根據個人特定基因組成和其他個人特徵量身定制預防、診斷和治療等醫療保健決策的醫療方法。這種治療利用基因測試和生物標記的數據來優化治療,並確保患者獲得最有效的藥物和最少的副作用。

個人化醫療應用包括藥物基因組學(根據個體的基因圖譜確定最佳藥物和劑量)、針對特定癌症的針對獨特分子標靶的標靶治療以及針對特定疾病的預防措施。

此外,個人化醫療利用先進技術和從人類基因組計劃等項目獲得的數據,透過提供更精確和專業的治療來改善患者的治療結果。

個人化醫療的全球市場動態

塑造個人化醫療市場的主要市場動態

主要市場驅動因子

癌症和遺傳疾病的盛行率不斷增加:

癌症和遺傳疾病的日益普及正在推動對個人化醫療技術的需求。根據世界衛生組織 (WHO) 的數據,癌症是全球頭號死因,2020 年將導致約 1,000 萬人死亡。國際癌症研究機構(IARC)預測,到2040年,全球癌症患者數將達到2,840萬,比2020年增加47%。癌症負擔的增加正在推動標靶治療和個人化治療方法的發展。

基因體定序技術的進展:

基因定序技術的快速進步使個人化醫療變得更加容易獲得和負擔得起。根據美國國家人類基因組研究所的數據,人類基因組定序的成本已從 2001 年的約 1 億美元大幅下降到 2021 年的不到 1,000 美元。這種顯著的成本降低增加了基因檢測在臨床實踐中的使用,並實現了個人化的治療選擇。

增加對精準醫療計畫的投資:

政府和企業正在增加對精準醫學研究和實施的投資。例如,美國國立衛生研究院 (NIH) 制定了“我們所有人研究與開發計劃”,該計劃收集了超過 100 萬美國人的數據,旨在加速研究並改善健康結果。截至 2023 年 9 月,該計劃已招募超過 746,000 人,超過 482,000 人提交了生物樣本進行基因組分析。這項大規模的努力反映了人們對擴大個人化醫療方法日益增長的興趣。

主要問題

醫療保健差距:

個人化醫療是基於主要從歐洲人群獲得的基因組數據,導致不同種族和民族群體的治療效果有偏差。這種低估導致演算法無法可靠地預測來自不同背景的患者的反應,從而擴大了現有的醫療保健差距。

監理監督:

隨著個人化醫療技術的進步,監管機構需要製定新標準,以評估其與傳統治療相比的安全性和有效性。這包括制定將遺傳和生物標記數據整合到臨床實踐中的指南。由於缺乏評估此類創新的臨床療效和成本效益的既定程序,阻礙了它們的批准和廣泛接受,限制了該領域的進展。

主要趨勢:

基因組診斷與標靶治療的整合:

隨著醫院越來越多地利用這些尖端技術,他們現在能夠根據患者獨特的 DNA 圖譜提供個人化的治療計劃。這一趨勢將提高醫療幹預的精確度,並實現更有效的疾病管理,包括癌症,可以根據特定的腫瘤特徵定製藥物,最終改善患者的治療結果和滿意度。

增加對數位健康解決方案的投資:

隨著遠距醫療、行動健康應用程式和穿戴式裝置的出現,可以持續監控患者的健康數據並即時更改治療方案。這些技術透過提供有關患者健康狀況和治療反應的資訊、促進更具協作性的醫療保健方法以及提高對個人化治療方案的依從性來增強患者的能力。

個人化營養與健康:

對個人化營養和健康的日益重視已成為個人化醫療市場的重要組成部分。隨著消費者的健康意識越來越強,對解決特定遺傳特徵和健康問題的個人化營養方案和補充劑的需求不斷增長。這一趨勢反映出人們對飲食如何影響健康和疾病管理有了更全面的了解,從而在解決特定健康問題的同時促進整體健康。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔
  • 調查手法

第2章 摘要整理

  • 主要調查結果
  • 市場概要
  • 市場亮點

第3章 市場概要

  • 市場規模與成長的可能性
  • 市場趨勢
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 波特的五力分析

第4章 個人化醫療市場:各產品類型

  • 個人化醫療診斷藥
  • 個人化醫療治療藥

第5章 個人化醫療市場:各用途

  • 腫瘤學
  • 神經學
  • 循環系統
  • 其他的用途

第6章 個人化醫療市場:各終端用戶

  • 醫院及診所
  • 研究機關及研究所
  • 製藥·生物科技企業
  • 患者

第7章 地區分析

  • 北美
  • 美國
  • 加拿大
  • 墨西哥
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 南美
  • 巴西
  • 阿根廷
  • 智利
  • 中東·非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第8章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • COVID-19對市場的影響

第9章 競爭情形

  • 主要企業
  • 市場佔有率分析

第10章 企業簡介

  • Roche
  • Illumina
  • Novartis
  • Amgen
  • Merck & Co., Inc.
  • Thermo Fisher Scientific
  • QIAGEN
  • Myriad Genetics
  • Exact Sciences Corporation
  • IQVIA
  • Syneos Health

第11章 市場展望和機會

  • 新興技術
  • 今後的市場趨勢
  • 投資機會

第12章 附錄

  • 簡稱清單
  • 出處和參考文獻
簡介目錄
Product Code: 7106

Personalized Medicine Market Size and Forecast

Personalized Medicine Market size was valued at USD 130.23 Billion in 2024 and is projected to reach USD 272.59 Billion by 2031 , growing at a CAGR of 10.67% from 2024 to 2031. Personalized medicine, also known as precision medicine, is a medical approach that tailors healthcare decisions-such as prevention, diagnosis, and treatment-to an individual's specific genetic composition and other personal traits. This practice uses data from genetic testing and biomarkers to optimize therapeutic actions, ensuring that patients receive the most effective medicines with the fewest negative effects.

Personalized medicine applications include pharmacogenomics, which helps determine the best medications and dosages for individuals based on their genetic profiles; targeted therapies for specific cancers that focus on unique molecular targets; and preventive measures informed by genetic predisposition to certain diseases.

Furthermore, personalized medicine uses advanced technologies and data from programs such as the Human Genome Project to improve patient outcomes by providing more precise and specialized treatment

Global Personalized Medicine Market Dynamics

The key market dynamics that are shaping the personalized medicine market include:

Key Market Drivers

Increasing Prevalence of Cancer and Genetic Disorders:

The increased prevalence of cancer and genetic disorders is pushing the need for personalized medicine techniques. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, accounting for approximately 10 million deaths in 2020. The International Agency for Research on Cancer (IARC) predicts that the worldwide cancer burden will reach 28.4 million cases in 2040, up 47% from 2020. The increasing cancer burden is driving the development of targeted treatments and personalized treatment approaches.

Advancements in Genomic Sequencing Technologies:

Rapid advancements in genetic sequencing technology are making customized medicine more accessible and inexpensive. According to the National Human Genome Research Institute, the cost of sequencing a human genome has decreased drastically, from approximately USD 100 Million in 2001 to less than $1,000 in 2021. This large cost reduction has resulted in increased usage of genetic testing in clinical settings, allowing for personalized treatment options.

Growing Investment in Precision Medicine Initiatives:

Governments and corporate entities are increasing their investments in precision medicine research and implementation. For example, the National Institutes of Health (NIH) in the United States developed the All of Us Research Program, which intends to collect data from one million or more Americans to speed up research and improve health outcomes. As of September 2023, the initiative had registered over 746,000 people, with over 482,000 submitting biosamples for genomic analysis. This large-scale endeavor reflects the growing interest in expanding personalized medicine approaches.

Key Challenges:

Healthcare Disparities:

Personalized medicine is based primarily on genomic data from European populations, which leads to therapeutic efficacy biases for varied racial and ethnic groups. This underrepresentation leads to algorithms that do not reliably anticipate reactions from patients from various backgrounds, increasing existing healthcare disparities.

Regulatory Oversight:

The development of new standards by regulatory bodies is necessary as personalized medicine technologies progress to assess their safety and effectiveness in comparison to conventional treatments. This includes developing guidelines for integrating genetic and biomarker data into clinical practice. The absence of established procedures for evaluating the clinical and cost-effectiveness of these innovations hampers their approval and widespread acceptance, limiting progress in this field.

Key Trends:

Integration of Genomic Diagnostics and Targeted Therapies:

Hospitals can now offer individualized treatment plans based on patient's unique DNA profiles as they use these cutting-edge technologies more frequently. This trend increases the accuracy of medical interventions, allowing for more effective disease management, such as cancer, where medications can be tailored to specific tumor characteristics, ultimately increasing patient outcomes and satisfaction.

Growing Investment in Digital Health Solutions:

The advent of telemedicine, mobile health apps, and wearable devices has enabled continuous monitoring of patient health data, allowing for real-time alterations to treatment programs. These technologies empower patients by providing them with information on their health and treatment responses, promoting a more collaborative approach to healthcare and increasing adherence to individualized treatment regimens.

Personalized Nutrition and Wellness:

There is a growing emphasis on tailored nutrition and wellness, which is emerging as a crucial area of the personalized medicine market. As customers become more health-conscious, there is a growing need for personalized dietary regimens and supplements that address specific genetic profiles and health concerns. This trend reflects a more comprehensive understanding of how diet affects health and illness management, resulting in creative solutions that promote overall well-being while addressing specific health concerns.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Personalized Medicine Market Regional Analysis

Here is a more detailed regional analysis of the personalized medicine market:

Asia Pacific:

According to Verified Market Research, the Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. The increased frequency of cancer and genetic illnesses in the Asia Pacific region is driving demand for personalized medical strategies. According to the International Agency for Research on Cancer (IARC), Asia accounted for over half of all new cancer cases worldwide in 2020, with an estimated 8.9 million new cases. According to the IARC, by 2040, this number will climb to around 14.5 million new cases per year in Asia. This rising cancer burden is driving investments in genetic research and personalized treatment strategies throughout the region.

Furthermore, the Asia Pacific region's population is rapidly growing and aging, creating demand for personalized healthcare solutions. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's population is predicted to grow from 4.3 billion in 2020 to 4.7 billion in 2050. Also, the population aged 65 and up is expected to more than quadruple, from 395 million in 2020 to 956 million by 2050. This generational transition is increasing the demand for more tailored and effective medical treatments, hence boosting the personalized medicine market.

North America:

North America is estimated to dominate the personalized medicine market during the forecast period. North America, particularly the United States, has a significant burden of chronic diseases that can be addressed using personalized medicine approaches. According to the Centers for Disease Control and Prevention (CDC), six out of every ten persons in the United States have a chronic disease, with four out of ten having two or more. In 2019, around 37.3 million Americans (11.3% of the total population) had diabetes. The rising frequency of chronic diseases creates a desire for more targeted and effective therapies provided by personalized medicine.

Furthermore, North America has a well-developed healthcare infrastructure that easily accepts new technology, helping the adoption of personalized medicine. According to the US Food and Drug Administration (FDA), the number of approved personalized medicines has increased significantly. In 2022, personalized medicines accounted for 25% of all new drug approvals, up from 5% in 2005. This trend reflects the region's ability to translate research into practical applications, hence boosting the expansion of the personalized medicine market.

Global Personalized Medicine Market: Segmentation Analysis

The Personalized Medicine Market is segmented based on Product, End-User, and Geography.

Personalized Medicine Market, By Product

  • Personalized Medicine Diagnostics
  • Personalized Medicine Therapeutics
  • Personalized Medical Care
  • Personalized Nutrition & Wellness

Based on Product, the market is segmented into Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, and Personalized Nutrition & Wellness. The personalized medicine diagnostics segment is estimated to dominate the personalized medicine market. This dominance is primarily driven by the growing demand for improved diagnostic tools capable of detecting genetic variants and biomarkers associated with a variety of disorders, including cancer. The rising frequency of chronic diseases needs more precise diagnostic procedures, resulting in increased investment in genetic testing and direct-to-consumer diagnostics.

Personalized Medicine Market, By End-User

  • Hospitals
  • Diagnostic Centers
  • Research & Academic Institutes
  • Others

Based on End-User, the Personalized Medicine Market is divided into Hospitals, Diagnostic Centers, Research & Academic Institutes, and Others. The hospital segment is estimated to dominate the market over the forecast period due to hospitals' crucial role as key providers of personalized healthcare services, which incorporate genomic diagnostics and tailored medicines into patient care. Their specialized facilities and skills enable them to efficiently implement innovative treatment approaches, thereby driving the expansion of personalized medicine and determining its future clinical practice.

Personalized Medicine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the Personalized Medicine Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate the market during the forecasted period due to the region's superior healthcare infrastructure, significant R&D investments, and high rates of chronic diseases such as cancer and diabetes. Furthermore, the substantial presence of top biotech and pharmaceutical businesses promotes innovation and acceptance of customized medicine solutions, firmly establishing North America as a market leader.

Key Players

  • The "Personalized Medicine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • Roche, Illumina, Novartis, Amgen, Merck & Co., Inc., Thermo Fisher Scientific, QIAGEN, Myriad Genetics, Exact Sciences Corporation, IQVIA, and Syneos Health.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Personalized Medicine Market Recent Developments
  • In September 2023, Agilent Technologies and Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) signed a Memorandum of Understanding (MOU) to advance gene and cell therapy over the next three years.
  • In July 2023, Pillar Biosciences and Illumina announced a strategic alliance to commercialize Pillar's range of oncology assays globally. Completing the agreement will provide unprecedented Next-Generation Sequencing (NGS) technologies, increasing patient access to individualized cancer treatment options.

TABLE OF CONTENTS

1. Introduction

  • Market Definition
  • Market Segmentation
  • Research Methodology

2. Executive Summary

  • Key Findings
  • Market Overview
  • Market Highlights

3. Market Overview

  • Market Size and Growth Potential
  • Market Trends
  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Porter's Five Forces Analysis

4. Personalized Medicine Market, By Product Type

  • Individualized Medical Care Diagnostics
  • Individualized Medical Care Therapeutics

5. Personalized Medicine Market, By Application

  • Oncology
  • Neurology
  • Cardiology
  • Additional Uses

6. Personalized Medicine Market, By End User

  • Hospitals and Clinics
  • Research Institutions and Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Patients

7. Regional Analysis

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Latin America
  • Brazil
  • Argentina
  • Chile
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

8. Market Dynamics

  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Impact of COVID-19 on the Market

9. Competitive Landscape

  • Key Players
  • Market Share Analysis

10. Company Profiles

  • Roche
  • Illumina
  • Novartis
  • Amgen
  • Merck & Co., Inc.
  • Thermo Fisher Scientific
  • QIAGEN
  • Myriad Genetics
  • Exact Sciences Corporation
  • IQVIA
  • Syneos Health

11. Market Outlook and Opportunities

  • Emerging Technologies
  • Future Market Trends
  • Investment Opportunities

12. Appendix

  • List of Abbreviations
  • Sources and References